{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T22:20:56Z","timestamp":1772144456887,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-US-989-5880"],"award-info":[{"award-number":["IN-US-989-5880"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018578","name":"Clinical and Translational Science Institute, Boston University","doi-asserted-by":"publisher","award":["1UL1TR001430"],"award-info":[{"award-number":["1UL1TR001430"]}],"id":[{"id":"10.13039\/100018578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eprac.2023.12.016","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T23:16:25Z","timestamp":1704410185000},"page":"270-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety-Net Primary Care and Endocrinology Clinicians\u2019 Knowledge and\u00a0Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A\u00a0Mixed-Methods Evaluation"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2949-9568","authenticated-orcid":false,"given":"Kathryn L.","family":"Fantasia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Austad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpan","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle T.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Walkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari-Lynn","family":"Drainoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2023.12.016_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.016_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2023.12.016_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100809","article-title":"Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis","volume":"30","author":"Petrelli","year":"2022","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.eprac.2023.12.016_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.eprac.2023.12.016_bib5","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.eprac.2023.12.016_bib6","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.016_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"21","key":"10.1016\/j.eprac.2023.12.016_bib8","first-page":"5019","article-title":"What do we know about inequalities in NAFLD distribution and outcomes? A scoping review","volume":"10","author":"Talens","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.016_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/hep.20554","article-title":"Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease","volume":"41","author":"Weston","year":"2005","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.016_bib10","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006326","article-title":"Racial\/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems","volume":"96","author":"Balasubramanian","year":"2017","journal-title":"Med (Baltim)"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.016_bib11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/19485565.2020.1765732","article-title":"Obesity and metabolic outcomes in a safety-net health system","volume":"65","author":"Huynh","year":"2020","journal-title":"Biodemography Soc Biol"},{"key":"10.1016\/j.eprac.2023.12.016_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211042200","article-title":"Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey","volume":"14","author":"Saeed","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.eprac.2023.12.016_bib13","series-title":"Advocacy, communication and social mobilization for TB control: a guide to developing knowledge, attitude and practice surveys","author":"World Health Organization","year":"2008"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.016_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)-\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.eprac.2023.12.016_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1748-5908-7-37","article-title":"Validation of the theoretical domains framework for use in behaviour change and implementation research","volume":"7","author":"Cane","year":"2012","journal-title":"Implement Sci"},{"issue":"3","key":"10.1016\/j.eprac.2023.12.016_bib16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2307\/30036540","article-title":"User acceptance of information technology: toward a unified view","volume":"27","author":"Venkatesh","year":"2003","journal-title":"MIS Q"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.016_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"issue":"6","key":"10.1016\/j.eprac.2023.12.016_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14799","article-title":"An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary care","volume":"39","author":"Gracen","year":"2022","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.eprac.2023.12.016_bib19","first-page":"2707","article-title":"Clinicians\u2019 perspectives on barriers and facilitators for the adoption of non-invasive liver tests for NAFLD: a mixed-method study","volume":"11","author":"Vali","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.eprac.2023.12.016_bib20","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/tbm\/ibz080","article-title":"Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study","volume":"10","author":"Hallsworth","year":"2021","journal-title":"Transl Behav Med"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2023.12.016_bib21","first-page":"S46","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.016_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.016_bib23","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/17474124.2021.1974295","article-title":"Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review","volume":"15","author":"Schattenberg","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2023.12.016_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13012-015-0295-0","article-title":"Use of concept mapping to characterize relationships among implementation strategies and assess their feasibility and importance: results from the Expert Recommendations for Implementing Change (ERIC) study","volume":"10","author":"Waltz","year":"2015","journal-title":"Implement Sci"},{"issue":"2","key":"10.1016\/j.eprac.2023.12.016_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jgh.15221","article-title":"Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease","volume":"36","author":"Vadarlis","year":"2021","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2023.12.016_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.eprac.2023.12.016_bib27","article-title":"Glucagon-like peptide-1 receptor agonists for\u00a0non-alcoholic fatty liver disease in type 2 diabetes: a meta-analysis","volume":"12","author":"Wong","year":"2021","journal-title":"Front\u00a0Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.eprac.2023.12.016_bib28","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.amjmed.2021.06.041","article-title":"The intersection of behavioral economics and the general medicine literature","volume":"134","author":"Reed","year":"2021","journal-title":"Am J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24000132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:15:41Z","timestamp":1761516941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24000132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1530891X24000132"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.016","relation":{"is-basis-for":[{"id-type":"doi","id":"10.52843\/cassyni.nygjq0","asserted-by":"object"}]},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety-Net Primary Care and Endocrinology Clinicians\u2019 Knowledge and\u00a0Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A\u00a0Mixed-Methods Evaluation","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}